Published in Stem Cells on October 18, 2007
Glycosaminoglycan-binding hydrogels enable mechanical control of human pluripotent stem cell self-renewal. ACS Nano (2012) 1.20
In vitro immunogenicity of undifferentiated pluripotent stem cells (PSC) and derived lineages. Semin Immunopathol (2011) 0.84
Culture conditions affect cardiac differentiation potential of human pluripotent stem cells. PLoS One (2012) 0.83
Twisting immune responses for allogeneic stem cell therapy. World J Stem Cells (2009) 0.78
Challenges for the Therapeutic use of Pluripotent Stem Derived Cells. Front Physiol (2012) 0.77
The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med (2011) 2.08
Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med (2012) 2.05
Elimination of antibodies to recombinant enzyme in Pompe's disease. N Engl J Med (2009) 1.99
Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells. Mol Genet Metab (2012) 1.79
Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood (2007) 1.52
Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet Med (2012) 1.31
Peripheral expression of self-MHC-II influences the reactivity and self-tolerance of mature CD4(+) T cells: evidence from a lymphopenic T cell model. Immunity (2002) 1.22
Atypical immunologic response in a patient with CRIM-negative Pompe disease. Mol Genet Metab (2011) 1.14
Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT. PLoS One (2013) 1.14
Biomarkers and surrogate endpoints in renal transplantation: present status and considerations for clinical trial design. Am J Transplant (2004) 0.95
Regulatory T cells in γ irradiation-induced immune suppression. PLoS One (2012) 0.91
Scientific considerations for generic synthetic salmon calcitonin nasal spray products. AAPS J (2010) 0.89
Letter to the Editors: Concerning "CRIM-negative Pompe disease patients with satisfactory clinical outcomes on enzyme replacement therapy" by Al Khallaf et al. J Inherit Metab Dis (2013) 0.89
CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy. Genet Med (2015) 0.89
The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease. Am J Med Genet C Semin Med Genet (2012) 0.83
Skin allograft rejection. Curr Protoc Immunol (2009) 0.83
A novel function of RNAs arising from the long terminal repeat of human endogenous retrovirus 9 in cell cycle arrest. J Virol (2012) 0.79
Signaling through MHC in transgenic mice generates a population of memory phenotype cytolytic cells that lack TCR. Blood (2003) 0.77
Apolipoprotein B binding domains: evidence that they are cell-penetrating peptides that efficiently deliver antigenic peptide for cross-presentation of cytotoxic T cells. J Immunol (2011) 0.76
CD4+ T-cell responses to self-peptide--MHC. Trends Immunol (2003) 0.75
Langerhans cell dogma: another round of rejections. J Invest Dermatol (2008) 0.75
An overview of cytokines and cytokine antagonists as therapeutic agents. Ann N Y Acad Sci (2009) 0.75
Microbial Risk in Pharmaceutical Manufacturing and ICH Q9. PDA J Pharm Sci Technol (2013) 0.75
CORRIGENDUM: CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy. Genet Med (2015) 0.75
A convenient method for positive selection of retroviral producing cells generating vectors devoid of selectable markers. J Virol Methods (2004) 0.75